{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T01:58:31Z","timestamp":1755223111200,"version":"3.43.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Roche Molecular Systems"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40121-025-01186-3","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T09:41:15Z","timestamp":1752486075000},"page":"1815-1827","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Detection of SARS-CoV-2 in Settings Including Point-of-Care: Performance of the Cobas SARS-CoV-2 NAT and Utility with the Cobas Liat System"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2032-8559","authenticated-orcid":false,"given":"Myrto","family":"Bolanaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7691-3709","authenticated-orcid":false,"given":"Martin","family":"M\u00f6ckel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Dodoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6325-0136","authenticated-orcid":false,"given":"Karen","family":"Gilliam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1737-3228","authenticated-orcid":false,"given":"Elissa","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2512-351X","authenticated-orcid":false,"given":"D. Jane","family":"Hata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"issue":"10223","key":"1186_CR1","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","volume":"395","author":"N Chen","year":"2020","unstructured":"Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507\u201313. https:\/\/doi.org\/10.1016\/S0140-6736(20)30211-7.","journal-title":"Lancet"},{"key":"1186_CR2","unstructured":"World Health Organization. Coronavirus disease (COVID-19) pandemic. https:\/\/www.who.int\/europe\/emergencies\/situations\/covid-19. Accessed 27 Nov 2024."},{"key":"1186_CR3","unstructured":"World Health Organization. WHO Coronavirus (COVID-19) dashboard. https:\/\/covid19.who.int\/. Updated 10 Nov 2024. Accessed 27 Nov 2024."},{"issue":"18","key":"1186_CR4","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"WJ Guan","year":"2020","unstructured":"Guan WJ, Ni ZY, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2002032.","journal-title":"N Engl J Med"},{"key":"1186_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.7452","author":"KL Bajema","year":"2025","unstructured":"Bajema KL, Bui DP, Yan L, Li Y, Rajeevan N, Vergun R, et al. Severity and long-term mortality of COVID-19, influenza, and respiratory syncytial virus. JAMA Intern Med. 2025. https:\/\/doi.org\/10.1001\/jamainternmed.2024.7452.","journal-title":"JAMA Intern Med"},{"issue":"1","key":"1186_CR6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/14737159.2018.1419065","volume":"18","author":"K Basile","year":"2018","unstructured":"Basile K, Kok J, Dwyer DE. Point-of-care diagnostics for respiratory viral infections. Expert Rev Mol Diagn. 2018;18(1):75\u201383. https:\/\/doi.org\/10.1080\/14737159.2018.1419065.","journal-title":"Expert Rev Mol Diagn"},{"issue":"9","key":"1186_CR7","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1002\/jmv.25781","volume":"92","author":"Q Ding","year":"2020","unstructured":"Ding Q, Lu P, Fan Y, Xia Y, Liu M. The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan. China J Med Virol. 2020;92(9):1549\u201355. https:\/\/doi.org\/10.1002\/jmv.25781.","journal-title":"China J Med Virol"},{"issue":"6","key":"1186_CR8","doi-asserted-by":"publisher","first-page":"2000562","DOI":"10.1183\/13993003.00562-2020","volume":"55","author":"WH Liang","year":"2020","unstructured":"Liang WH, Guan WJ, Li CC, Li Y, Liang H, Zhao Y, et al. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China. Eur Respir J. 2020;55(6):2000562. https:\/\/doi.org\/10.1183\/13993003.00562-2020.","journal-title":"Eur Respir J"},{"key":"1186_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ijsu.2020.05.018","volume":"79","author":"E Abbasi-Oshaghi","year":"2020","unstructured":"Abbasi-Oshaghi E, Mirzaei F, Farahani F, Khodadadi I, Tayebinia H. Diagnosis and treatment of coronavirus disease 2019 (COVID-19): laboratory, PCR, and chest CT imaging findings. Int J Surg. 2020;79:143\u201353. https:\/\/doi.org\/10.1016\/j.ijsu.2020.05.018.","journal-title":"Int J Surg"},{"issue":"Suppl 3","key":"1186_CR10","doi-asserted-by":"publisher","first-page":"S139","DOI":"10.1093\/cid\/cit578","volume":"57","author":"AM Caliendo","year":"2013","unstructured":"Caliendo AM, Gilbert DN, Ginocchio CC, Hanson KE, May L, Quinn TC, et al. Better tests, better care: improved diagnostics for infectious diseases. Clin Infect Dis. 2013;57(Suppl 3):S139\u201370. https:\/\/doi.org\/10.1093\/cid\/cit578.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1186_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcvp.2023.100166","volume":"3","author":"M Mozgovoj","year":"2023","unstructured":"Mozgovoj M, Graham M, Ferrufino C, Blanc S, Souto AF, Pilloff M, et al. Viral load in symptomatic and asymptomatic patients infected with SARS-CoV-2. What have we learned? J Clin Virol Plus. 2023;3(4):100166. https:\/\/doi.org\/10.1016\/j.jcvp.2023.100166.","journal-title":"J Clin Virol Plus."},{"issue":"9","key":"1186_CR12","doi-asserted-by":"publisher","first-page":"Cd013718","DOI":"10.1002\/14651858.CD013718","volume":"9","author":"M Viswanathan","year":"2020","unstructured":"Viswanathan M, Kahwati L, Jahn B, Giger K, Dobrescu AI, Hill C, et al. Universal screening for SARS-CoV-2 infection: a rapid review. Cochrane Database Syst Rev. 2020;9(9):CD013718. https:\/\/doi.org\/10.1002\/14651858.CD013718.","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"1186_CR13","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1586\/14737159.2014.960516","volume":"14","author":"DA McPartlin","year":"2014","unstructured":"McPartlin DA, O\u2019Kennedy RJ. Point-of-care diagnostics, a major opportunity for change in traditional diagnostic approaches: potential and limitations. Expert Rev Mol Diagn. 2014;14(8):979\u201398. https:\/\/doi.org\/10.1586\/14737159.2014.960516.","journal-title":"Expert Rev Mol Diagn"},{"issue":"2","key":"1186_CR14","doi-asserted-by":"publisher","first-page":"e02811","DOI":"10.1128\/jcm.02811-20","volume":"59","author":"G Hansen","year":"2021","unstructured":"Hansen G, Marino J, Wang ZX, Beavis KG, Rodrigo J, Labog K, et al. Clinical performance of the point-of-care cobas Liat for detection of SARS-CoV-2 in 20 minutes: a multicenter study. J Clin Microbiol. 2021;59(2):e02811-e2820. https:\/\/doi.org\/10.1128\/jcm.02811-20.","journal-title":"J Clin Microbiol"},{"issue":"1","key":"1186_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcvp.2021.100012","volume":"1","author":"LO Fukasawa","year":"2021","unstructured":"Fukasawa LO, Sacchi CT, Gon\u00e7alves MG, Lemos APS, Almeida SCG, Caterino-de-Araujo A. Comparative performances of seven quantitative reverse-transcription polymerase chain reaction assays (RT-qPCR) for detecting SARS-CoV-2 infection in samples from individuals suspected of COVID-19 in S\u00e3o Paulo, Brazil. J Clin Virol Plus. 2021;1(1): 100012. https:\/\/doi.org\/10.1016\/j.jcvp.2021.100012.","journal-title":"J Clin Virol Plus"},{"issue":"2","key":"1186_CR16","doi-asserted-by":"publisher","first-page":"e03716","DOI":"10.1128\/spectrum.03716-22","volume":"11","author":"R Munir","year":"2023","unstructured":"Munir R, Scott LE, Noble LD, Steegen K, Hans L, Stevens WS. Performance evaluation of four qualitative RT-PCR assays for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Microbiol Spectr. 2023;11(2):e03716-e3722. https:\/\/doi.org\/10.1128\/spectrum.03716-22.","journal-title":"Microbiol Spectr"},{"key":"1186_CR17","unstructured":"Roche Diagnostics. cobas\u00ae SARS-CoV-2. Nucleic acid test for use on the cobas\u00ae liat system. https:\/\/diagnostics.roche.com\/global\/en\/products\/lab\/cobas-sars-cov-2-liat-rmd-liat-sars-003.html#productInfo. Updated 12 Dec 2024. Accessed 12 Dec 2024."},{"key":"1186_CR18","unstructured":"US Food and Drug Administration. 510(k) Substantial equivalence determination decision summary. cobas SARS-CoV-2 nucleic acid test for use on the cobas Liat System. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/reviews\/K223783.pdf. Accessed 16 Jan 2024."},{"key":"1186_CR19","unstructured":"Roche Diagnostics. cobas SARS-COV-2. Qualitative assay for use on the cobas 6800\/8800 Systems. Instructions for use. https:\/\/www.fda.gov\/media\/136049\/download?attachment. Updated 30 Aug 2024. Accessed 12 Dec 2024."},{"key":"1186_CR20","unstructured":"US Food & Drug Administration. Emergency Use Authorization. cobas\u00ae SARS-CoV-2. Qualitative assay for use on the cobas\u00ae 6800\/8800 Systems. 2021. https:\/\/www.fda.gov\/media\/136046\/download?attachment. Accessed 26 Feb 2025."},{"key":"1186_CR21","unstructured":"Roche Diagnostics. CE IVD. cobas\u00ae SARS-CoV-2 Qualitative. Nucleic acid test for use on the cobas\u00ae 6800\/8800 Systems. 2021. https:\/\/elabdoc-prod.roche.com\/eLD\/api\/downloads\/c0618754-836d-ec11-0f91-005056a71a5d?countryIsoCode=XG. Accessed 26 Feb 2025."},{"key":"1186_CR22","unstructured":"Roche Diagnostics. cobas SARS-CoV-2 Nucleic acid test for use on the cobas Liat System - English - US-IVD. https:\/\/elabdoc-prod.roche.com\/eLD\/api\/downloads\/fe6bf2b6-dd87-ef11-2691-005056a772fd?countryIsoCode=XG. Updated 10 Nov 2024. Accessed 12 Dec 2024."},{"key":"1186_CR23","unstructured":"Centre for Disease Control and Prevention. COVID Data Tracker. Trends in United States COVID-19 deaths, emergency department (ED) visits, and test positivity by geographic area. https:\/\/covid.cdc.gov\/covid-data-tracker\/#trends_weeklydeaths_testpositivity_00. Updated 9 Dec 2024. Accessed 12 Dec 2024."},{"key":"1186_CR24","unstructured":"European Centre for Disease Prevention and Control. Overview of respiratory virus epidemiology in the EU\/EEA. https:\/\/erviss.org\/. Updated 1 Dec 2024. Accessed 12 Dec 2024."},{"issue":"10","key":"1186_CR25","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01278-21","volume":"59","author":"D Blackall","year":"2021","unstructured":"Blackall D, Moreno R, Jin J, Plotinsky R, Dworkin R, Oethinger M. Performance characteristics of the Roche Diagnostics cobas Liat PCR System as a COVID-19 screening tool for hospital admissions in a regional health care delivery system. J Clin Microbiol. 2021;59(10):e0127821. https:\/\/doi.org\/10.1128\/jcm.01278-21.","journal-title":"J Clin Microbiol"},{"issue":"13","key":"1186_CR26","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.3390\/diagnostics13132245","volume":"13","author":"R Egerer","year":"2023","unstructured":"Egerer R, Edel B, Hornung F, Deinhardt-Emmer S, Baier M, Lewejohann J-C, et al. SARS-CoV-2 testing of emergency department patients using cobas\u00ae Liat\u00ae and eazyplex\u00ae rapid molecular assays. Diagnostics (Basel). 2023;13(13):2245. https:\/\/doi.org\/10.3390\/diagnostics13132245.","journal-title":"Diagnostics (Basel)"},{"issue":"2","key":"1186_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2263","volume":"32","author":"M Naseri","year":"2021","unstructured":"Naseri M, Ziora Z, Simon G, Batchelor W. ASSURED-compliant point-of-care diagnostics for the detection of human viral infections. Rev Med Virol. 2021;32(2):e2263. https:\/\/doi.org\/10.1002\/rmv.2263.","journal-title":"Rev Med Virol"},{"issue":"1","key":"1186_CR28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41564-018-0295-3","volume":"4","author":"KJ Land","year":"2019","unstructured":"Land KJ, Boeras DI, Chen XS, Ramsay AR, Peeling RW. REASSURED diagnostics to inform disease control strategies, strengthen health systems and improve patient outcomes. Nat Microbiol. 2019;4(1):46\u201354. https:\/\/doi.org\/10.1038\/s41564-018-0295-3.","journal-title":"Nat Microbiol"},{"key":"1186_CR29","unstructured":"US Food & Drug Administration. In vitro diagnostics EUAs\u2014molecular diagnostic tests for SARS-CoV-2. 2023. https:\/\/www.fda.gov\/medical-devices\/covid-19-emergency-use-authorizations-medical-devices\/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2. Updated 19 Nov 2024. Accessed 27 Nov 2024."}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01186-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-025-01186-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01186-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T11:56:44Z","timestamp":1754913404000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-025-01186-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1186"],"URL":"https:\/\/doi.org\/10.1007\/s40121-025-01186-3","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"type":"print","value":"2193-8229"},{"type":"electronic","value":"2193-6382"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Myrto Bolanaki, Jane Hata, and Bruce White have nothing to disclose. Martin M\u00f6ckel has received consulting and speakers\u2019 fees from Roche Diagnostics and Thermo Fisher Scientific. Christopher Dodoo, Karen Gilliam and Elissa Robbins are employees of Roche Diagnostics. Elissa Robbins is a stockholder of Roche Diagnostics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in compliance with the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) and Good Clinical Practice Guidelines, and the Helsinki Declaration of 1964 and its later amendments. Institutional review board approval was obtained for each participating study site before study start (Institutional Ethical Review Board of the Charit\u00e9-Universit\u00e4tsmedizin Berlin (reference number: EA2\/119\/23) and Mayo Clinic Florida Institutional Review Board (reference number: 23-000144). All participants aged 18\u00a0years or older provided written informed consent; all participants aged less than 18\u00a0years had written informed consent provided on their behalf by a legal guardian.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}